Abstract
Genomic blood biomarkers hold great promise for development of novel clinical and therapeutic approaches in patients with neurodegenerative diseases. Such biomarkers could prove invaluable in early disease diagnosis, monitoring of disease progression, or assessment of response to therapy. More importantly, they could be helpful in search for disease-modifying new therapies which are very much needed in modern approaches to treatment of neurodegenerative diseases, serving as surrogate endpoints in clinical trials. However, when performing expression profiling experiments aimed at discovery of new biomarker genes, standard operating procedures regarding sample collection, microarray methodology, and statistical analysis need to be fully developed and strictly adhered to. Several studies performed on patients with multiple sclerosis, Huntingtons, Parkinsons and Alzheimers disease offer promise that such approaches might prove useful in clinical practice. Crucial for successful application of any genomic biomarker will be confirmation in multiple independent patient cohorts and correlation of the improvement in biomarker endpoint with clinical improvement in longitudinal patient studies.
Keywords: Biomarker, genomics, microarray, neurodegenerative disease, multiple sclerosis, high-throughput transcriptomic analysis, cell extraction, myelin antigens, cDNA microarray technology, cAMP, STRL 22, apoptosis, DNA fragmentation factor-45, immunomodulatory therapy, interferon therapy, Huntington Disease, Huntinngton's Disease Rating Scale, PBMC, PCR, Parkinson's Disease, bradykinesia, (akynesia), ubiquitin-proteasome pathway, LRPPRC, Alzheimer's Disease, amyloid precursor protein, SORL1, real-time PCR, MMChip, RNA extraction
CNS & Neurological Disorders - Drug Targets
Title: Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases
Volume: 9 Issue: 6
Author(s): Fran Borovecki and Mario Habek
Affiliation:
Keywords: Biomarker, genomics, microarray, neurodegenerative disease, multiple sclerosis, high-throughput transcriptomic analysis, cell extraction, myelin antigens, cDNA microarray technology, cAMP, STRL 22, apoptosis, DNA fragmentation factor-45, immunomodulatory therapy, interferon therapy, Huntington Disease, Huntinngton's Disease Rating Scale, PBMC, PCR, Parkinson's Disease, bradykinesia, (akynesia), ubiquitin-proteasome pathway, LRPPRC, Alzheimer's Disease, amyloid precursor protein, SORL1, real-time PCR, MMChip, RNA extraction
Abstract: Genomic blood biomarkers hold great promise for development of novel clinical and therapeutic approaches in patients with neurodegenerative diseases. Such biomarkers could prove invaluable in early disease diagnosis, monitoring of disease progression, or assessment of response to therapy. More importantly, they could be helpful in search for disease-modifying new therapies which are very much needed in modern approaches to treatment of neurodegenerative diseases, serving as surrogate endpoints in clinical trials. However, when performing expression profiling experiments aimed at discovery of new biomarker genes, standard operating procedures regarding sample collection, microarray methodology, and statistical analysis need to be fully developed and strictly adhered to. Several studies performed on patients with multiple sclerosis, Huntingtons, Parkinsons and Alzheimers disease offer promise that such approaches might prove useful in clinical practice. Crucial for successful application of any genomic biomarker will be confirmation in multiple independent patient cohorts and correlation of the improvement in biomarker endpoint with clinical improvement in longitudinal patient studies.
Export Options
About this article
Cite this article as:
Borovecki Fran and Habek Mario, Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237476
DOI https://dx.doi.org/10.2174/187152710793237476 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Markers of Tumor Progression in Melanoma
Current Genomics A Designed β-Hairpin Forming Peptide Undergoes a Consecutive Stepwise Process for Self-Assembly into Nanofibrils
Protein & Peptide Letters Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model
Anti-Cancer Agents in Medicinal Chemistry Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects
Mini-Reviews in Medicinal Chemistry Evaluation of a Dramatic Writing Workshop in Youth With or Without Psychiatric Disorders
Adolescent Psychiatry Characteristics of Insomniacs Having Sleep State Misperception
Neuroscience and Biomedical Engineering (Discontinued) Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Message from the Editor-in-Chief:
CNS & Neurological Disorders - Drug Targets Oral and Written Naming in Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Erythropoietin Gene Polymorphism rs551238 is Associated with a Reduced Susceptibility to Brain Injury in Preterm Infants
Current Neurovascular Research Food as a Bariatric Drug
Current Pharmaceutical Design The Synthetic Potential and Chemical Aspects of the Gewald Reaction: Application in the Preparation of 2-Aminothiophenes and Related Heterocycles
Current Organic Synthesis Neuroimaging of Consciousness and Sleep Spindles
Recent Patents on Medical Imaging Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Docking Investigation on Bis (Nitro Indazolyl) Methanes; Synthesis and Antimicrobial Activity Towards Breast Cancer Applications
Letters in Organic Chemistry Pharmacology of Appetite Suppression: Implication for the Treatment of Obesity
Current Drug Targets Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Parental Reports of Prodromal Psychopathology in Pediatric Bipolar Disorder
Current Neuropharmacology Acknowledgements to Reviewers:
Current Alzheimer Research